Is secukinumab effective for psoriatic arthritis with insufficient response to initial treatment?

Abstract

INTRODUCTION:

Psoriatic arthritis is an inflammatory arthritis without a clear etiology. Biological therapy has become key for its treatment, especially in more severe cases. There are several alternatives for biological treatment, including secukinumab. However, it is not clear how effective and safe it is, which is particularly relevant considering its high cost.

METHODS:

To answer this question we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach.

RESULTS AND CONCLUSIONS:

We identified eight systematic reviews including three randomized trials overall. We concluded secukinumab in psoriatic arthritis leads to an improvement of disease activity and symptoms, and it is probably not associated to severe adverse events.

• Authors: Soledad Venegas-Iribarren, Romina Andino-Navarrete
• Journal: Medwave (Medwave) Vol. 17 Issue 9 Pg. e7101 (Dec 20 2017) ISSN: 0717-6384 [Electronic] Chile
• Vernacular Title: ¿Es efectivo el secukinumab para la artritis psoriática que no responde a tratamiento inicial?
• PMID: 29272266 (Publication Type: Journal Article, Meta-Analysis, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• secukinumab

Topics

• Antibodies, Monoclonal (adverse effects, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Arthritis, Psoriatic (drug therapy, physiopathology)
• Databases, Factual
• Humans
• Randomized Controlled Trials as Topic
• Treatment Outcome